secwatch.observer — SEC 8-K summary
======================================

Issuer:     Assertio Holdings, Inc. (ASRT)
CIK:        0001808665
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001808665-26-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M
--------------------------------------------------------------------------------

- Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.
- Sympazan net sales grew to $3.1M from $2.5M; Indocin flat at $5.5M.
- Gross margin improved to 75% from 61% on product mix and inventory write-downs in prior year.
- Adjusted EBITDA loss $4.1M vs income $3.4M last year; cash dropped to $63.4M from $93.4M in Q3.
- FY2026 guidance: net product sales $110M-$125M, Adj EBITDA $28M-$40M; CEO prioritizes Rolvedon and disciplined oncology build.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/0001808665-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808665/000180866526000010/asrt-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001808665-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer